Kymera Therapeutics, Inc.
Every calculator, already run for KYMR
Open the full toolkit →You have the numbers on KYMR. Get the argument.
A written report on which of these readings actually decide the outcome for Kymera Therapeutics, Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
23 analysts covering KYMRAnalyst Price Target Disagreement for Kymera Therapeutics, Inc.
Wall Street's bull case implies +61% from the current price; the bear case implies -1%. A 62% spread signals high analyst disagreement — run your own DCF to anchor on fundamentals rather than street consensus.
Ownership & short interest
Insider Trading Activity for KYMR
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing KT-621, an oral STAT6 degrader in Phase 2b clinical trials for moderate to severe atopic dermatitis, asthma, COPD, EoE, CRSwNP, CSU, PN, BP, and others; KT-579, an oral IRF5 degrader in Phase 1 trials for autoimmune diseases such as systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, SSc, DM, and others; KT-485/SAR447971, IRAK4 program, which is in Phase II clinical trial for the treatment of…
KYMR — frequently asked
Is KYMR a buy right now?
Wall Street's consensus rating on Kymera Therapeutics, Inc. is Strong Buy across 23 analysts, with a mean price target of $138.64 (+24% vs. the current $112.00). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
When is KYMR's next earnings date?
Kymera Therapeutics, Inc. is next scheduled to report earnings around Nov 3, 2026. A full KYMR research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
What is the analyst price target disagreement for Kymera Therapeutics, Inc.?
Analysts covering Kymera Therapeutics, Inc. (KYMR) range from a bear-case target of $111.00 to a bull-case high of $180.00, with a mean consensus target of $138.64 across 22 analysts. The spread of $69.00 (62% of the current price) indicates high disagreement on the outlook. Run the DCF calculator to build your own estimate independent of street consensus.
Compare Kymera Therapeutics, Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Kymera Therapeutics, Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full KYMR research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Kymera Therapeutics, Inc., in minutes. 3 free reports included with every account — no credit card required.